PD07.03. Real-World Data on the Management of Double Primary Squamous Cell Carcinoma of the Esophagus and Head and Neck

Clicks: 16
ID: 326046
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #436 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Esophageal squamous cell carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC) frequently develop as double primary cancers through field cancerization, driven by shared risk factors such as alcohol consumption and tobacco smoking. Immune checkpoint inhibitors (ICIs), particularly programmed death-1 (PD-1) inhibitors, have become standard therapies for both ESCC and HNSCC, necessitating a reassessment of treatment strategies for patients with double primary cancers. However, real-world clinical practice regarding PD-1 inhibitor use in this population remains poorly characterized. Therefore, we evaluated treatment patterns and their association with overall survival (OS) using real-world data (RWD) from our institution. Methods We retrospectively analyzed 37 patients with double primary ESCC and HNSCC treated with systemic therapy between 2018 and 2023 using our institutional cancer registry linked to the CyberOncology RWD platform. Treatment patterns, programmed death-ligand (PD-L1) expression, ICI use, and OS were evaluated. Results Among 37 patients (94.6% male; median age 65.1 years), 62.2% were heavy smokers and 32.4% heavy drinkers. PD-L1 combined positive score was <1 in 17 and ≥20 in 14 of 31 evaluable patients. ICIs were given to 19 (61.3%) with immune-related adverse events in 3 (9.7%), without a difference in 1-year OS. HNSCC was prioritized for treatment in 78.4% of cases, while ESCC remained untreated in 40.5% of cases. After HNSCC chemoradiotherapy (CRT), ESCC was treated by surgery (n=2), CRT (n=1), or endoscopic submucosal dissection (ESD) (n=6); three ESD-treated patients died from HNSCC. One patient developed cervical hemorrhage after HNSCC CRT, delaying surgery for stage I ESCC, leading to fatal progression. Conclusion Using real-world data, we comprehensively characterized treatment patterns in patients with double primary ESCC and HNSCC. Untreated ESCC did not generally compromise overall survival; however, in selected cases, ESCC could be treated after successful HNSCC therapy, whereas in others, progression of ESCC adversely affected prognosis. These findings highlight the need for individualized treatment strategies that account for the stage of each tumor and the dynamic impact of treatment sequencing in patients with concurrent cancers.
Reference Key
openalex_W7203977631 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sakiko Naito, Hayato Yamaguchi, Takahiro Muramatsu, Yasuyuki Kagawa, Kumiko Uchida, Takashi Morise, Yoshiya Yamauchi, Isaku Okamoto, Masakatsu Fukuzawa, Kiyoaki Tsukahara, Manabu Muto, Takao Itoi
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.125
URL
https://doi.org/10.1093/dote/doag077.125
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.